Recent News

Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)

Athenex Provides First Quarter 2022 Financial Results and Business Update

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma at the ASG

Athenex to Provide Corporate and Financial Update for the First Quarter 2022 on May 10, 2022

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (“Tandem”) Meetings of ASTCT and CIBMTR

Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

CORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022

Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 15, 2022

Athenex Announces Appointment of Chief Financial Officer

Our Science

We are focused on discovering and developing novel therapies for treating cancer and addressing unmet medical needs.

Learn more

Investors

View press releases, events and presentations, and other investment information

Learn more

Join Our Team

As the Company grows, we are always looking to add talented professionals to join the Athenex family.

Learn more